Exscientia Raises $510 million IPO

Company profile · Healthcare & Life Sciences · Updated Recent

Exscientia has raised $510M in IPO funding led by Various, with participation from Various (IPO). first AI-designed drug in clinical trials. The funds will be used to Advance Centaur Chemist AI pipeline of 10+ clinical compounds.

IPO$510 millionTotal tracked $510 millionOxford, UK

What it does

AI drug design — first AI-designed drug in clinical trials

Traction

Various participated in the latest tracked round; deeper traction analysis is held until source support is strong enough.

Trend impact

MD-grade thesis held: available source material is not specific enough to support a non-generic investor-economist read without overclaiming.

Funding history

Recent · IPO · $510 million · Various

Products & services

World Artificial Intelligence Drug Discovery - Market Analysis, capability
Forecast, Size, Trends and Insights - IndexBox. World Artificial capability
Intelligence Drug Discovery - Market Analysis, Forecast, Size, Trends capability
Insights - IndexBox capability
IndexBox Quotient Sciences advances AI-designed drug product into Phase capability

Open Exscientia in the interactive Capvizr dashboard →